The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

Inhibitors of the DNA damage signaling kinase ATR increase tumor cell killing by chemotherapies that target DNA replication forks but also kill rapidly proliferating immune cells including activated T cells. Nevertheless, ATR inhibitor (ATRi) and radiotherapy (RT) can be combined to generate CD8(+)...

Descripción completa

Detalles Bibliográficos
Autores principales: Vendetti, Frank P., Pandya, Pinakin, Clump, David A., Schamus-Haynes, Sandra, Tavakoli, Meysam, diMayorca, Maria, Islam, Naveed M., Chang, Jina, Delgoffe, Greg M., Beumer, Jan H., Bakkenist, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977511/
https://www.ncbi.nlm.nih.gov/pubmed/36810257
http://dx.doi.org/10.1172/jci.insight.165615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977511/
https://www.ncbi.nlm.nih.gov/pubmed/36810257
http://dx.doi.org/10.1172/jci.insight.165615

Ejemplares similares